Direct targeting of glycolysis can be achieved by administering an inhibitor such as NCI-737 to lactate dehydrogenase A (LDHA), the main enzyme responsible for the Warburg effect that has shown promise as an anti-cancer agent in preclinical trials (17). The gene discussed is LDHA; the disease is cancer.